Pharming Group N.V.

NasdaqGM:PHAR Stock Report

Market Cap: US$881.7m

Pharming Group Future Growth

Future criteria checks 3/6

Pharming Group is forecast to grow earnings and revenue by 28.2% and 11.8% per annum respectively while EPS is expected to grow by 40.9% per annum.

Key information

28.2%

Earnings growth rate

40.90%

EPS growth rate

Biotechs earnings growth24.9%
Revenue growth rate11.8%
Future return on equityn/a
Analyst coverage

Low

Last updated26 May 2026

Recent future growth updates

Recent updates

Seeking Alpha • Feb 04

Pharming Group: Crossing From Speculation To Profitability

Summary Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, and generated $44M in operating cash flow, supporting financial independence. Key near-term catalysts include FDA approval for Joenja's pediatric label and pivotal data from leniolisib and KL1333 clinical programs. The company's commercial infrastructure and pipeline expansion position it for significant upside as rare disease market opportunities broaden. Read the full article on Seeking Alpha
Seeking Alpha • Apr 01

Pharming Group: Small Dutch Company With Strong Revenues

Summary Pharming Group, a Dutch biotech firm, excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow despite low US trading volume. RUCONEST and JOENJA drive revenue, with RUCONEST contributing $252.2M and JOENJA surging 147% to $45M in its first full year. Acquired KL1333, a promising late-stage molecule for mitochondrial diseases, enhancing their pipeline and expanding market potential. Despite low US trading volume, Pharming Group's robust financials and growth prospects make it a compelling investment for those with access to Euronext. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Pharming's rare immunodeficiency disorder drug gets FDA priority review

The U.S. Food and Drug Administration ((FDA) granted priority review to Pharming (NASDAQ:PHAR) application seeking approval of oral drug leniolisib to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in patients 12 years of age and older in the U.S. The FDA accepted the company's New Drug Application (NDA) and is expected to make a decision by March 29, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 2/3 study of leniolisib, which met its co-primary goals of reduction in index lymph node size and correction of immunodeficiency, the Netherlands-based company said in a Sept. 28 press release. APDS is a rare immunodeficiency disease that affects 1 to 2 people per million and is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells, according to the company.
Seeking Alpha • Aug 01

Pharming gets EMA panel nod for accelerated review of leniolisib for rare immunodeficiency disorder

A committee of the European Medicines Agency (EMA) granted accelerated assessment for Pharming's (NASDAQ:PHAR) potential application seeking approval of leniolisib to treat patients aged 12 years and older with activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS). The company said it plans to submit the marketing authorization application (MAA) to the EMA in October. Pharming noted that an accelerated assessment reduces the timeframe for review by the EMA's Committee for Medicinal Products for Human Use (CHMP) to 150 days from 210 days. The company said clinical development for leniolisib includes positive data from a phase 2/3 trial. APDS is a rare immunodeficiency disease that affects 1 to 2 people per million and is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells, the company said in an Aug. 1 press release.

Earnings and Revenue Growth Forecasts

NasdaqGM:PHAR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20284233492N/A3
12/31/20274484661685
12/31/20264044339434
3/31/2026369125656N/A
12/31/202537635455N/A
9/30/202536205353N/A
6/30/2025340-83031N/A
3/31/2025321-1456N/A
12/31/2024297-12-3-2N/A
9/30/2024286-1800N/A
6/30/2024278-13-6-6N/A
3/31/2024258-1118-2N/A
12/31/2023245-113-17N/A
9/30/2023219-22-4-24N/A
6/30/2023206-165-15N/A
3/31/2023202-2-3-1N/A
12/31/2022206142022N/A
9/30/2022204302533N/A
6/30/2022202211526N/A
3/31/2022202111731N/A
12/31/2021199162138N/A
9/30/2021200222943N/A
6/30/2021200314052N/A
3/31/2021202375970N/A
12/31/2020212386884N/A
9/30/2020212447085N/A
6/30/2020202465993N/A
3/31/2020202425384N/A
1/1/202018941N/A74N/A
9/30/201917538N/A70N/A
6/30/201917534N/A63N/A
3/31/201915829N/A57N/A
12/31/201815529N/A46N/A
9/30/2018152-29N/A63N/A
6/30/2018138-44N/A61N/A
3/31/2018128-80N/A52N/A
12/31/2017108-91N/A46N/A
9/30/201776-53N/A14N/A
6/30/201747-47N/A-6N/A
3/31/201731-21N/A-13N/A
12/31/201617-18N/A-11N/A
9/30/201612-16N/A-18N/A
6/30/201612-15N/A-18N/A
3/31/201613-14N/A-18N/A
12/31/201512-11N/A-19N/A
9/30/2015298N/A-3N/A
6/30/2015279N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHAR's forecast earnings growth (28.2% per year) is above the savings rate (3.5%).

Earnings vs Market: PHAR's earnings (28.2% per year) are forecast to grow faster than the US market (17.1% per year).

High Growth Earnings: PHAR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PHAR's revenue (11.8% per year) is forecast to grow slower than the US market (11.9% per year).

High Growth Revenue: PHAR's revenue (11.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PHAR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 14:00
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharming Group N.V. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH